Pazopanib: in advanced renal cell carcinoma
M Sanford, GM Keating - BioDrugs, 2010 - Springer
M Sanford, GM Keating
BioDrugs, 2010•SpringerPazopanib is an orally administered, multi-tyrosine kinase inhibitor that interrupts tumor
growth in renal cell carcinoma. In a randomized, double-blind, placebo-controlled,
multinational trial in patients with locally advanced or metastatic renal cell carcinoma, the
median progression-free survival (PFS) of patients who were treated with pazopanib 800 mg
once daily was significantly longer than that of placebo recipients (9.2 vs 4.2 months; hazard
ratio 0.46 [95% CI 0.34, 0.62]). In prespecified analyses in treatment-naive and cytokine …
growth in renal cell carcinoma. In a randomized, double-blind, placebo-controlled,
multinational trial in patients with locally advanced or metastatic renal cell carcinoma, the
median progression-free survival (PFS) of patients who were treated with pazopanib 800 mg
once daily was significantly longer than that of placebo recipients (9.2 vs 4.2 months; hazard
ratio 0.46 [95% CI 0.34, 0.62]). In prespecified analyses in treatment-naive and cytokine …
Abstract
Pazopanib is an orally administered, multi-tyrosine kinase inhibitor that interrupts tumor growth in renal cell carcinoma.
In a randomized, double-blind, placebo-controlled, multinational trial in patients with locally advanced or metastatic renal cell carcinoma, the median progression-free survival (PFS) of patients who were treated with pazopanib 800 mg once daily was significantly longer than that of placebo recipients (9.2 vs 4.2 months; hazard ratio 0.46 [95% CI 0.34, 0.62]).
In prespecified analyses in treatment-naive and cytokine-pretreated patients, grouped according to prior treatment history, age, sex, Memorial Sloan-Kettering Cancer Center risk category, and Eastern Cooperative Oncology Group performance status, median PFS was significantly longer in pazopanib than placebo recipients in all subgroups.
Pazopanib recipients also had a significantly higher overall response rate than placebo recipients; in pazopanib recipients, the median time to response was 11.9 weeks and the median duration of response was 58.7 weeks.
Oral pazopanib had an acceptable tolerability profile in patients with advanced renal cell carcinoma. Adverse events were common in pazopanib and placebo recipients and were mostly of mild to moderate severity.
Springer
